Matrixx Case Is Already Shaping Disclosure Strategies – Experts
This article was originally published in The Tan Sheet
Executive Summary
In light of arguments before the Supreme Court concerning shareholders' complaint against Matrixx Initiatives, securities law attorneys advise firms not to rely on a statistical significance standard for disclosing reports of problems with a product.
You may also be interested in...
Matrixx Decision Raises More Disclosure Questions – Law Professor
The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.
Matrixx Decision Raises More Disclosure Questions – Law Professor
The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.
Matrixx Decision Raises More Disclosure Questions – Law Professor
The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.